Description
Esentra 120 mg contains Denosumab, a fully human monoclonal antibody that targets the RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) protein. It is widely used in oncology to manage bone-related complications associated with cancer.
🔬 Mechanism of Action
Denosumab binds to RANKL and prevents its interaction with the RANK receptor on osteoclasts. As a result, it:
- Inhibits osteoclast formation and activity
- Reduces bone resorption
- Strengthens bone structure
- Lowers the risk of fractures and other skeletal complications
💊 Indications
Esentra 120 mg is indicated for:
- Prevention of skeletal-related events in patients with bone metastases from solid tumors
- Multiple Myeloma with bone involvement
- Giant Cell Tumor of Bone (GCTB)
- Hypercalcemia of malignancy refractory to bisphosphonates
📌 Key Features
- Strength: 120 mg
- Dosage Form: Subcutaneous injection
- Therapeutic Class: RANKL Inhibitor / Monoclonal Antibody
- Administration: Given as subcutaneous injection, typically every 4 weeks (as prescribed)
- Monitoring: Serum calcium levels and kidney function monitoring recommended
⚕️ Benefits
- Reduces skeletal complications such as fractures
- Helps control bone pain
- Improves bone strength in cancer patients
- Effective in patients resistant to bisphosphonates
⚠️ Precautions
- Risk of hypocalcemia; calcium and vitamin D supplementation required
- Rare risk of osteonecrosis of the jaw (ONJ)
- Monitor for infections and skin reactions
- Regular calcium level monitoring required
- Use under oncologist supervision
Esentra 120 mg (Denosumab Injection) is an advanced bone-targeted therapy that helps prevent skeletal complications, strengthen bones, and improve quality of life in patients with cancer-related bone involvement.
